BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Analysts at Jefferies Group cut their FY2017 EPS estimates for BioCryst Pharmaceuticals in a research report issued on Wednesday. Jefferies Group analyst M. Raycroft now forecasts that the biotechnology company will earn ($0.66) per share for the year, down from their previous forecast of ($0.61). Jefferies Group has a “Buy” rating and a $7.00 price objective on the stock. Jefferies Group also issued estimates for BioCryst Pharmaceuticals’ FY2018 earnings at ($0.58) EPS, FY2019 earnings at ($0.63) EPS, FY2020 earnings at ($0.53) EPS and FY2021 earnings at ($0.31) EPS.

BCRX has been the topic of a number of other research reports. BidaskClub raised BioCryst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, August 25th. HC Wainwright reissued a “buy” rating on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 8th. J P Morgan Chase & Co raised BioCryst Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $6.00 to $9.00 in a research note on Tuesday, September 5th. Zacks Investment Research raised BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.00 price target on the stock in a research note on Wednesday, August 9th. Finally, Royal Bank Of Canada assumed coverage on BioCryst Pharmaceuticals in a research note on Thursday, September 14th. They set a “sector perform” rating and a $6.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $9.13.

COPYRIGHT VIOLATION NOTICE: This story was first posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://www.watchlistnews.com/fy2017-eps-estimates-for-biocryst-pharmaceuticals-inc-bcrx-reduced-by-jefferies-group/1694787.html.

Shares of BioCryst Pharmaceuticals (NASDAQ BCRX) opened at $4.82 on Friday. BioCryst Pharmaceuticals has a fifty-two week low of $3.95 and a fifty-two week high of $9.25. The company has a quick ratio of 1.54, a current ratio of 2.53 and a debt-to-equity ratio of 0.21.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.18) EPS for the quarter, meeting analysts’ consensus estimates of ($0.18). The firm had revenue of $8.76 million for the quarter, compared to analysts’ expectations of $5.05 million. BioCryst Pharmaceuticals had a negative return on equity of 123.16% and a negative net margin of 167.58%. BioCryst Pharmaceuticals’s quarterly revenue was up 12.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.16) EPS.

Several institutional investors and hedge funds have recently modified their holdings of BCRX. RA Capital Management LLC raised its position in shares of BioCryst Pharmaceuticals by 47.9% in the 2nd quarter. RA Capital Management LLC now owns 5,162,242 shares of the biotechnology company’s stock worth $28,702,000 after buying an additional 1,672,447 shares during the period. FMR LLC raised its position in shares of BioCryst Pharmaceuticals by 114.5% in the 2nd quarter. FMR LLC now owns 3,124,676 shares of the biotechnology company’s stock worth $17,373,000 after buying an additional 1,667,791 shares during the period. Vanguard Group Inc. raised its position in shares of BioCryst Pharmaceuticals by 49.1% in the 1st quarter. Vanguard Group Inc. now owns 5,011,763 shares of the biotechnology company’s stock worth $42,098,000 after buying an additional 1,651,292 shares during the period. State Street Corp raised its position in shares of BioCryst Pharmaceuticals by 72.0% in the 2nd quarter. State Street Corp now owns 3,909,013 shares of the biotechnology company’s stock worth $21,736,000 after buying an additional 1,636,909 shares during the period. Finally, Jennison Associates LLC raised its position in shares of BioCryst Pharmaceuticals by 47.8% in the 3rd quarter. Jennison Associates LLC now owns 3,076,461 shares of the biotechnology company’s stock worth $16,121,000 after buying an additional 995,643 shares during the period. 70.12% of the stock is currently owned by institutional investors and hedge funds.

In related news, Director Fred E. Cohen sold 54,250 shares of the stock in a transaction on Monday, September 18th. The stock was sold at an average price of $5.42, for a total value of $294,035.00. Following the transaction, the director now directly owns 173,660 shares of the company’s stock, valued at approximately $941,237.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 5.80% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Earnings History and Estimates for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.